Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 150.06 · gapped above the open, then crossed back over prior close. High/low 158.00 at 4:00 am ET, 149.44 at 3:00 pm ET.
Neurocrine Biosciences Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of NBIX revenue | Skew |
|---|---|---|---|
| KRCKilroy Realty Corp | 2.10% | 0.91% | 2.3× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“For example, we depend on AbbVie for the manufacture and commercialization of ORILISSA and ORIAHNN and for the continued development of elagolix.”
FILING10-K0000914475-26-000007cik 0000914475
“Takeda Pharmaceutical Company Limited 37.5 7.5 —”
FILING10-K0000914475-26-000007cik 0000914475
“For 2024 compared to 2023, the decrease primarily reflected the payment of a $143.9 million upfront fee in 2023 pursuant to the expansion of our collaboration with Voyager.”
FILING10-K0000914475-26-000007cik 0000914475
“NBI‑921355 was in-licensed from Xenon Pharmaceuticals Inc. in 2019, and we retain global rights.”
FILING10-K0000914475-26-000007cik 0000914475
“12 Neurocrine Biosciences, Inc. (4) San Diego 16,365 299,064 2.1% 1.7% 2025 / 2029 / 2031 5.7”
$26M relationship2.3× more of KRC’s book than NBIX’s
basisKRC fy2025 · closed 2025-12 $1.2BNBIX fy2025 · closed 2025-12 $2.9B
FILING
“In May 2024, we exclusively licensed our ATXN2 program to Neurocrine Biosciences, Inc.”
FILING10-K0001193125-26-122778cik 0001842295disclosed by MAZE
“Nxera Pharma UK Limited $ 15.0 $ 50.0 $ —”
FILING10-K0000914475-26-000007cik 0000914475
“INGREZZA is marketed as DYSVAL ® (valbenazine) in Japan and REMLEAS ® (valbenazine) in other select Asian markets, where Tanabe Pharma Corporation (formerly Mitsubishi Tanabe Pharma Corporation) retains commercialization rights.”
FILING10-K0000914475-26-000007cik 0000914475
“We are dependent on our collaborators, including Neurocrine Biosciences, to fund and conduct the research and any clinical development of product candidates under our agreements with each of them, and for the successful regulatory approval, marketing and commercialization of one or more of such products or product candidates.”
FILING10-K0001193125-26-076650cik 0001582313disclosed by XENE
“This program represents the first biologic (peptide) to emerge from our internal discovery collaboration (with Sentia Medical Sciences, Inc.) on novel peptide CRF receptor antagonists, highlighting our expansion into biologics to complement our small-molecule portfolio.”
FILING10-K0000914475-26-000007cik 0000914475
Watchlist prices, news filtered to it, and its next report on your desk.
Neurocrine Biosciences Inc has 9 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either Neurocrine Biosciences Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
NBIX (Neurocrine Biosciences Inc) has 9 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: XENE −0.41%, in healthcare.